-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Group Iib in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Group IIb in Inflammation Drug Details:The drug candidate is under development for the treatment of inflammation....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Systolic Heart Failure Drug Details: KER-012 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Diastolic Heart Failure (HFpEF) Drug Details: KER-012 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteogenesis Imperfecta report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteogenesis Imperfecta Drug Details: KER-012 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteoporosis Drug Details: KER-012 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Non-Small Cell Lung Cancer Drug Details: LNS-8801 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in Non-Small Cell Lung Cancer Drug Details: BI-1206 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in B-Cell Non-Hodgkin Lymphoma Drug Details: BI-1206 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in Marginal Zone B-cell Lymphoma Drug Details: BI-1206 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Gastric Cancer Drug Details: LNS-8801 is under development for the...